International Journal of Chemical and Biochemical Sciences
(ISSN 2226-9614)

Journal Home page: www.iscientific.org/Journal.html

Coronary Microvascular Dysfunction: The Invisible Culprit in Ischemic Heart Disease

Mohamed Hussein[1]

[1] *Specialist cardiology Dubai hospital, Dubai, United Arab Emirates*

Abstract

Coronary microvascular dysfunction (CMD) is established as a key etiology for ischemic heart disease (IHD), particularly in non-obstructive coronary artery disease (NOCAD) patients, resulting in myocardial ischemia despite normal angiograms. Pathophysiology and clinical relevance continue to be poorly explored. To provide an overview of CMD pathogenesis, diagnosis, clinical importance, and management in the context of IHD. A literature review was done that incorporated data from the literature for CMD pathophysiology, risk factors, treatment, and diagnostic methods (including coronary flow reserve [CFR], positron emission tomography [PET], and magnetic resonance imaging [MRI]). CMD is caused by endothelial dysfunction, microvascular remodeling, reduction in vasodilation, and increase in microvascular resistance, and inflammation, all of which cause reduced myocardial perfusion. It is an important cause of ANOCA and HFpEF and presenting symptoms are exercise intolerance, breathlessness, and chest pain. It has predisposing factors in the form of hypertension, diabetes, obesity, smoking, and age. Investigation modalities like CFR (<2.0 for indicating dysfunction), PET, and MRI enhance the sensitivity of detection with invasive measurement of flow providing immediate feedback. Therapeutic agents encompass vasodilators (calcium blockers, nitrates), statins, ACE inhibitors, modification in lifestyle (smoking cessation, exercise, nutritious diet), and control over comorbidity. CMD shares similar poor cardiovascular prognoses with enhanced risks for myocardial infarction as well as mortality. CMD is a neglected yet significant cause of IHD leading to high morbidity in NOCAD and HFpEF. Enhanced diagnostic imaging and precision therapy offer the hope of early detection and treatment, highlighting the need for combined approaches to prevent IHD burden.

Keywords: Coronary microvascular dysfunction, ischemic heart disease, non-obstructive coronary artery disease, microvascular angina, coronary flow reserve.

Full length article **Corresponding Author*, e-mail: *mohamedgheita12@gmail.com*

1. Introduction

Coronary microvascular dysfunction (CMD) refers to abnormal functioning of the small blood vessels (microcirculation) of the heart, which plays a critical role in regulating myocardial blood flow. While pathophysiology of ischemic heart disease (IHD) is often attributed to obstructive coronary artery disease (CAD), growing evidence indicates that CMD can independently contribute to ischemia and adverse cardiovascular outcomes [1]. CMD, often considered an "invisible" cause of ischemic heart disease, is characterized by impaired vasodilation, endothelial dysfunction, and reduced myocardial perfusion in the absence of significant epicardial coronary artery stenosis. This literature review delves into the pathophysiology, diagnosis, clinical implications, and management strategies of coronary microvascular dysfunction, emphasizing its role in ischemic heart disease [2]. Coronary microvascular dysfunction is an often overlooked but critical contributor to ischemic heart disease. CMD plays a key role in conditions such as angina with non-obstructive coronary arteries and heart failure with preserved ejection fraction, leading to myocardial ischemia, exercise intolerance, and poor cardiovascular outcomes.

Early diagnosis and appropriate management of CMD through pharmacological treatment, lifestyle modifications, and control of underlying risk factors are essential for improving patient outcomes and reducing the burden of ischemic heart disease [3]. Ischemic heart disease (IHD) remains one of the leading causes of morbidity and mortality worldwide, primarily caused by the narrowing or occlusion of large coronary arteries due to atherosclerosis. However, a growing body of evidence suggests that coronary microvascular dysfunction (CMD) plays a significant role in ischemia and heart failure, particularly in patients who do not exhibit overt coronary artery disease (CAD) on traditional angiographic imaging. CMD refers to impaired function of the coronary microcirculation, which includes small coronary arteries and arterioles that regulate myocardial blood flow [4]. Often considered an "invisible" culprit due to its subtle presentation and lack of clear imaging markers, CMD is emerging as a crucial contributor to ischemic heart disease, especially in patients with non-obstructive coronary artery disease (NOCAD). This literature review aims to explore pathophysiology, diagnostic strategies, clinical implications, potential management of CMD in ischemic heart disease [5].

2. Pathophysiology of Coronary Microvascular Dysfunction

The coronary microcirculation consists of vessels with diameters less than 500 micrometers, including arterioles, capillaries, and venules. These microvessels are crucial for regulating blood flow and maintaining myocardial oxygen delivery. Coronary microvascular dysfunction (CMD) involves both structural and functional changes in the coronary microcirculation that impair ability of these vessels to adequately supply blood to heart muscle [6]. The coronary microvascular system consists of small blood vessels that control distribution of blood to myocardium (heart muscle). These microvessels play a vital role in maintaining myocardial oxygen delivery, particularly during times of increased demand (e.g., physical activity or stress). CMD arises when these small vessels fail to adequately dilate and perfuse heart tissue, leading to insufficient oxygen supply [7].

3. Key Mechanisms Involved in CMD

- Endothelial Dysfunction: The endothelium lining the coronary microvessels plays a critical role in regulating vascular tone and preventing vasoconstriction. Endothelial dysfunction, characterized by reduced nitric oxide (NO) bioavailability and increased endothelin-1 production, leads to impaired vasodilation, a hallmark of CMD [7].
- Microvascular Remodeling: Chronic CMD can lead to structural changes in the coronary microvessels, including thickening of the vessel wall and decreased capillary density, reducing the capacity for adequate myocardial perfusion [8].
- Impaired Vasodilation: In CMD, coronary microvessels show a reduced ability to dilate in response to stimuli such as adenosine, acetylcholine, or other vasodilators. This results in a mismatch between myocardial oxygen demand and supply, leading to ischemia, particularly under conditions of stress or exercise [9].
- Increased Microvascular Resistance: Elevated resistance in the coronary microcirculation further exacerbates ischemia by reducing myocardial blood flow, especially in the absence of significant epicardial coronary disease. This phenomenon is often referred to as "microvascular angina [10].
- Inflammation and Oxidative Stress: Inflammatory cytokines, such as C-reactive protein (CRP), and oxidative stress contribute to endothelial dysfunction and impaired vasodilation. This is especially relevant in conditions like diabetes, hypertension, and metabolic syndrome, which are known risk factors for CMD [11].

4. Coronary Microvascular Dysfunction and Ischemic Heart Disease (IHD)

CMD has become recognized as an important contributor to ischemic heart disease, particularly in patients with angina and normal coronary arteries (i.e., non-obstructive coronary artery disease or NOCAD). These patients experience symptoms of ischemia, but conventional angiography fails to reveal significant coronary artery stenosis. The role of CMD in ischemic heart disease is multifaceted [12].

- Angina with Non-Obstructive Coronary Arteries (ANOCA): In patients with angina but no significant coronary stenosis, CMD is often the underlying cause. Reduced coronary microvascular function leads to myocardial ischemia, even in the absence of epicardial coronary artery disease. This condition, referred to as microvascular angina, is characterized by chest pain, exertional dyspnea, and exercise intolerance. In patients with chest pain but no significant coronary artery stenosis (i.e., non-obstructive coronary artery disease), CMD is often responsible for inducing myocardial ischemia. This condition, referred to as microvascular angina, presents with symptoms similar to angina caused by CAD, including chest pain, shortness of breath, and exercise intolerance, despite normal coronary angiograms [13].
- Link to Cardiovascular Risk Factors: CMD is more prevalent in individuals with traditional cardiovascular risk factors, including hypertension, diabetes, and hyperlipidemia. These factors contribute to endothelial dysfunction, increased oxidative stress, and impaired vasodilation, all of which are associated with an increased risk of IHD. In ANOCA, the coronary microvessels are unable to dilate appropriately during times of increased myocardial demand, leading to a mismatch between oxygen supply and demand. As a result, patients experience ischemic symptoms despite the absence of large vessel blockages [14].
- Association with Adverse Cardiovascular Outcomes: CMD has been linked to worse outcomes in patients with ischemic heart disease, including an increased risk of heart failure with preserved ejection fraction (HFpEF), myocardial infarction, and overall cardiovascular mortality. The presence of CMD in IHD patients is associated with poorer prognosis, even when traditional coronary artery disease is absent or mild [15].
- Heart Failure with Preserved Ejection Fraction (HFpEF): CMD is a significant contributor to the pathophysiology of HFpEF. In these patients, impaired microvascular function leads to inadequate oxygen supply to the myocardium, exacerbating the heart's inability to meet the metabolic demands of the body despite preserved systolic function. This results in exercise intolerance and dyspnea, common symptoms of HFpEF [16].

5. Diagnostic Approaches for Coronary Microvascular Dysfunction

The diagnosis of CMD is challenging because it often occurs in the absence of visible coronary artery disease on standard imaging techniques such as coronary angiography. Several methods have been developed to assess microvascular function [17].

1) Coronary Flow Reserve (CFR)

- CFR is one of the most widely used measures to assess coronary microvascular function. It is calculated as the ratio of blood flow in coronary artery during hyperemia (increased flow, typically induced by adenosine) to baseline flow. A reduced CFR (typically <2.0) indicates impaired coronary microvascular function [18].

2) Doppler Flow Velocity Measurement

- This technique uses coronary Doppler ultrasound to measure velocity of blood flow in coronary microvessels. A reduced flow velocity during hyperemia suggests impaired microvascular function [19].

3) Positron Emission Tomography (PET)

- PET imaging can measure myocardial blood flow and coronary flow reserve. It is considered one of the gold standard techniques for assessing microvascular function, particularly in patients with suspected CMD and normal angiograms [20].

4) Magnetic Resonance Imaging (MRI)

- Cardiac MRI with contrast can be used to assess myocardial perfusion and detect regional ischemia caused by CMD. MRI can also evaluate the structural integrity of the coronary microvessels, providing additional insights into microvascular health [21].

5) Invasive Assessments: Pressure and Flow Measurements

- Invasive techniques, such as the measurement of coronary artery pressure and flow using a guidewire (e.g., the thermodilution technique), can be used to evaluate microvascular function during coronary angiography. These techniques allow for real-time measurement of microvascular resistance and flow [22].

6. Risk Factors and Coronary Microvascular Dysfunction

Several cardiovascular risk factors are strongly associated with development and progression of CMD [23].

- Hypertension: Elevated blood pressure increases the workload on the heart and exacerbates endothelial dysfunction, leading to microvascular impairment.
- Diabetes: Chronic hyperglycemia is known to damage the endothelium and impair microvascular function through various mechanisms, including increased oxidative stress and inflammatory cytokine production.
- Obesity and Metabolic Syndrome: These conditions are associated with systemic inflammation, increased sympathetic nervous system activity, and endothelial dysfunction, all of which contribute to the development of CMD.
- Smoking: Smoking leads to endothelial dysfunction, increased oxidative stress, and impaired coronary vasodilation, all of which are key contributors to CMD.
- Aging: Age-related changes in the coronary microvasculature, such as reduced endothelial nitric oxide production and increased vascular stiffness, contribute to the development of CMD [24].

7. Management of Coronary Microvascular Dysfunction

Effective management of CMD focuses on treating underlying risk factors, improving endothelial function, and optimizing myocardial perfusion [25].

- Pharmacological Approaches:
  - Vasodilators: Medications that improve coronary vasodilation, such as nitrates or calcium channel blockers, may help alleviate symptoms of CMD and improve myocardial oxygen delivery.
  - Statins: Statins, by lowering cholesterol and reducing inflammation, have shown potential benefits in improving microvascular function and reducing cardiovascular risk in patients with CMD.
  - Angiotensin-Converting Enzyme Inhibitors (ACE-Is): ACE inhibitors can improve endothelial function and have been shown to be beneficial in managing CMD, particularly in patients with hypertension or diabetes.
  - Aspirin and Antiplatelet Therapy: While CMD does not typically involve significant thrombotic events, antiplatelet therapy may be helpful in managing underlying inflammation and reducing the risk of further vascular damage [17].
- Lifestyle Modifications
  - Physical Activity: Regular exercise has been shown to improve endothelial function, reduce inflammation, and enhance coronary microvascular health.
  - Diet: A heart-healthy diet rich in antioxidants, omega-3 fatty acids, and low in processed foods can help improve vascular health and reduce oxidative stress.
  - Smoking Cessation and Weight Management: Quitting smoking and maintaining a healthy weight can reduce the progression of CMD and improve overall cardiovascular health.
- Management of Comorbid Conditions: Controlling hypertension, diabetes, and hyperlipidemia is essential in reducing the risk of CMD and its associated complications [12].

8. Conclusion

Coronary microvascular dysfunction is a significant, yet often overlooked, contributor to ischemic heart disease. It is a key factor in conditions like angina with non-obstructive coronary arteries, heart failure with preserved ejection fraction, and adverse cardiovascular outcomes in patients with risk factors such as hypertension, diabetes, and obesity [3]. Diagnosis remains challenging, but advancements in imaging techniques like coronary flow reserve (CFR), PET, and MRI are improving our ability to detect CMD. Early identification and appropriate management of CMD through lifestyle modifications, pharmacological therapy, and control of underlying risk factors can help reduce the cardiovascular burden and improve patient outcomes. Understanding and addressing CMD as a distinct pathological entity is crucial in improving the management of ischemic heart disease and related conditions [9].

Funding: None to be declared

Conflicting Interest: The authors declare that they have no conflicting interests.

References

[1] J.H. Chong, M. Abdulkareem, S.E. Petersen, M.Y. Khanji. (2022). Artificial intelligence and cardiovascular magnetic resonance imaging in myocardial infarction patients. Current problems in cardiology. 47(12): 101330.

[2] A. Milzi, F. Simonetto, A. Landi. (2025). Percutaneous Revascularization of Thrombotic and Calcified Coronary Lesions. Journal of Clinical Medicine. 14(3): 692.

[3] S. Aydemir, S.Ş. Aydın, O. Altınkaya, E. Aksakal, M. Özmen. (2025). Evaluation of hematological and biochemical parameters that predict the no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention. Angiology. 00033197251320141.

[4] M.F. Di Carli. (2021). Nuclear Cardiology and Multimodal Cardiovascular Imaging, E-Book: A

Companion to Braunwald's Heart Disease. Elsevier Health Sciences. 20(39): 216.

[5] M.S. Alqahtani, M. Abbas, A. Alsabaani, A. Alqarni, H.M. Almohiy, E. Alsawqaee, R. Alshahrani, S. Alshahrani. (2022). The potential impact of COVID-19 virus on the heart and the circulatory system. Infection and drug resistance. 1175-1189.

[6] H.A. Awnuur. (2024). Myocardial Infarction With Non-Obstructive Coronary Arteries. Lithuanian University of Health Sciences (Lithuania).

[7] B.-K. Koo, D. Hwang, S. Park, S. Kuramitsu, T. Yonetsu, C.H. Kim, J. Zhang, S. Yang, J.-H. Doh, Y.-H. Jeong. (2023). Practical application of coronary physiologic assessment: asia-pacific expert consensus document: Part 2. JACC: Asia. 3(6): 825-842.

[8] I. Krishnan-Sivadoss, I.A. Mijares-Rojas, R.A. Villarreal-Leal, G. Torre-Amione, A.A. Knowlton, C.E. Guerrero-Beltrán. (2021). Heat shock protein 60 and cardiovascular diseases: An intricate love-hate story. Medicinal research reviews. 41(1): 29-71.

[9] F.L. Gurgoglione, L. Vignali, R.A. Montone, R. Rinaldi, G. Benatti, E. Solinas, A.M. Leone, D. Galante, G. Campo, S. Biscaglia. (2024). Coronary spasm testing with acetylcholine: A powerful tool for a personalized therapy of coronary vasomotor disorders. Life. 14(3): 292.

[10] M.K. Mahowald, K. Esmail, F.M. Ezzeddine, C. Choi, H. Mieszczanska, G. Velarde. (2024). Sex disparities in cardiovascular disease. Methodist DeBakey Cardiovascular Journal. 20(2): 107.

[11] J. Kwiecinski, E. Tzolos, M.C. Williams, D. Dey, D. Berman, P. Slomka, D.E. Newby, M.R. Dweck. (2023). Noninvasive coronary atherosclerotic plaque imaging. Cardiovascular Imaging. 16(12): 1608-1622.

[12] I. Pires, M. Mapelli, N. Amelotti, E. Salvioni, C. Ferrari, A. Baggiano, E. Conte, I. Mattavelli, P. Agostoni. (2022). Case Report: Acute Heart Failure Induced by the Combination of Takayasu's, Takotsubo and Coronary Vasospasm in an Elementary School Teacher–A Reaction to Return-to-Work Stress After COVID-19? Frontiers in Psychiatry. 13: 882870.

[13] A. Samaras, D.V. Moysidis, A.S. Papazoglou, G. Rampidis, P.N. Kampaktsis, K. Kouskouras, G. Efthymiadis, A. Ziakas, N. Fragakis, V. Vassilikos. (2023). Diagnostic puzzles and cause-targeted treatment strategies in myocardial infarction with non-obstructive coronary arteries: an updated review. Journal of Clinical Medicine. 12(19): 6198.

[14] G. Cimmino, L. Di Serafino, P. Cirillo. (2022). Pathophysiology and mechanisms of acute coronary syndromes: atherothrombosis, immune-inflammation, and beyond. Expert review of cardiovascular therapy. 20(5): 351-362.

[15] M. Camilli, M. Russo, R. Rinaldi, A. Caffè, G. La Vecchia, A. Bonanni, G. Iannaccone, M. Basile, R. Vergallo, C. Aurigemma. (2022). Air pollution and coronary vasomotor disorders in patients with myocardial ischemia and unobstructed coronary arteries. Journal of the American College of Cardiology. 80(19): 1818-1828.

[16] O. Demeulenaere, P. Mateo, R. Ferrera, P.-M. Chiaroni, A. Bizé, J. Dai, L. Sambin, R. Gallet, M. Tanter, C. Papadacci. (2023). Assessment of coronary microcirculation alterations in a porcine model of no-reflow using ultrasound localization microscopy: a proof of concept study. EBioMedicine. 94.

[17] J. Takahashi, S. Onuma, K. Hao, S. Godo, T. Shiroto, S. Yasuda. (2024). Pathophysiology and diagnostic pathway of myocardial infarction with non-obstructive coronary arteries. Journal of Cardiology. 83(1): 17-24.

[18] G. Occhipinti, C. Bucciarelli-Ducci, D. Capodanno. (2021). Diagnostic pathways in myocardial infarction with non-obstructive coronary artery disease (MINOCA). European Heart Journal Acute Cardiovascular Care. 10(7): 813-822.

[19] A. Lopez-Candales, K. Sawalha, T. Asif. (2024). Nonobstructive epicardial coronary artery disease: an evolving concept in need of diagnostic and therapeutic guidance. Postgraduate Medicine. 136(4): 366-376.

[20] A.V. Sharma, J.A. Ambrose. (2023). Pathophysiology of Ischemic Syndromes in Coronary Artery Disease. Ischemic Heart Disease: From Diagnosis to Treatment. 67-81.

[21] N. Fabin, M. Bergami, E. Cenko, R. Bugiardini, O. Manfrini. (2022). The role of vasospasm and microcirculatory dysfunction in fluoropyrimidine-induced ischemic heart disease. Journal of Clinical Medicine. 11(5): 1244.

[22] I. Borzillo, O. De Filippo, R. Manai, F. Bruno, E. Ravetti, A.A. Galanti, R. Vergallo, I. Porto, G.M. De Ferrari, F. D'Ascenzo. (2023). Role of intracoronary imaging in myocardial infarction with non-obstructive coronary disease (MINOCA): a review. Journal of Clinical Medicine. 12(6): 2129.

[23] Z. Yang, Y. Liu, Z. Li, S. Feng, S. Lin, Z. Ge, Y. Fan, Y. Wang, X. Wang, J. Mao. (2023). Coronary microvascular dysfunction and cardiovascular disease: Pathogenesis, associations and treatment strategies. Biomedicine & Pharmacotherapy. 164: 115011.

[24] X. Chang, A. Lochner, H.-H. Wang, S. Wang, H. Zhu, J. Ren, H. Zhou. (2021). Coronary microvascular injury in myocardial infarction: perception and knowledge for mitochondrial quality control. Theranostics. 11(14): 6766.

[25] N. Mileva, S. Nagumo, T. Mizukami, J. Sonck, C. Berry, E. Gallinoro, G. Monizzi, A. Candreva, D. Munhoz, D. Vassilev. (2022). Prevalence of coronary microvascular disease and coronary vasospasm in patients with nonobstructive coronary artery disease: systematic review and meta-analysis. Journal of the American Heart Association. 11(7): e023207.